Nanomedical Diagnostics, a U.S-based producer of graphene biosensors for pharmaceutical and biotherapeutics research, has announced a headquarters relocation, effectively tripling its space from 5,200 to 16,500 square feet.
“This past year has seen exponential growth, both domestically and internationally, for the sales of our drug discovery platforms. We’re in the great position of having to move to a new space to accommodate expanded production and R&D,” says Nanomedical Diagnostics CEO, Ross Bundy. “Our new building enables better operational efficiencies for our production lines and brings departments that were formerly separated in different locations together under one roof. This allows for better collaboration and innovation as we launch new products and grow our staff.”